Abstract Background HIV-1 integrase (IN) variability in treatment naïve patients with different
HIV-1 subtypes is a major issue. In fact, the effect of previous exposure to antiretrovirals …

HIV-1 integrase enzyme is responsible for the integration of viral DNA into the host genomic
DNA. Integrase strand transfer inhibitors (INSTIs) are highly potent antiretroviral agents that …

Background Integrase inhibitors are recently prescribed to multi-class drug resistant HIV-1
patients in Hong Kong. Unlike pol gene, there are no FDA-approved genotypic resistance …

Steegen and colleagues reported results from a national survey in South Africa aimed at
determining the prevalence of antiretroviral drug resistance in patients who are not …

The aim of this study was to characterize the genotypic and phenotypic resistance profile to
the integrase strand transfer inhibitor (INSTI) bictegravir (BIC) and other INSTIs in patients …

To the Editors: An estimated 36.9 million people are living with HIV-1 worldwide, 1 of which
there are approximately 75,500 infected people in Canada. 2 Although varied prevention …

Integrase strand transfer inhibitor (INSTI)-containing regimens in HIV-1-infected patients
have experienced a global increase. Recently, WHO has emphasized the need to fast-track …

Background Despite the scale-up of ART and the rollout in Tanzania of dolutegravir, an
integrase strand transfer inhibitor (INSTI), treatment success has not been fully realized. HIV …

Integrase (IN) plays an essential role in HIV-1 replication, by mediating integration of the
viral genome into the host cell genome. IN is a potential target of antiretroviral (ARV) …

Abstract Background: Four Integrase Strand Transfer Inhibitors (INSTIs) have been
approved for HIV-1 by the Food and Drug Administration (FDA). Recently, resistance against …